Chief Judge Connolly Issues Comprehensive Opinion Setting Forth Court’s Findings Of Fact And Conclusions Of Law On Infringement Claims And Invalidity Defenses As To Patents-In-Suit Following ANDA Trial

Fox Rothschild LLP
Contact

Fox Rothschild LLP

By Memorandum Opinion entered by The Honorable Colm F. Connolly in Pharmacyclics LLC et al. v. Alvogen Pine Brook LLC et al., Civil Action No. 19-0434-CFC-CJB (D.Del. August 19, 2021), the Court set forth its findings of fact and conclusions of law on the asserted infringement claims and invalidity defenses with respect to U.S. Patent Nos. 8,008,309 (“the ‘309 patent”), 8,754,090 (“the ‘090 patent”), 9,655,857 (“the ‘857 patent”), and 9,725,455 (“the ‘455 patent”) following a seven-day bench trial.  Plaintiffs’ claims centered under the Hatch Waxman Act, 21 U.S.C. § 355(j), and arose out of Defendants’ submission of an Abbreviated New Drug Application (ANDA) to the U.S. Food & Drug Administration (FDA) seeking approval to market generic versions of Plaintiffs’ brand-name drug Imbruvica®.  Plaintiffs asserted infringement of the four patents-in-suit by Defendants’ ANDA product and Defendants asserted numerous invalidity defenses for the patents asserted against them.

Among its numerous findings of fact and conclusions of law contained in the Opinion, the Court concluded that the ‘309 patent is not invalid due to anticipation by the Pan article.  Id. at *13-31.  In reaching that conclusion, the Court found that claim 10 of the ‘309 patent has a priority filing date of September 22, 2006 – the date of the #720 provisional application; is presumed to have been invented on that date; and, therefore could not have been anticipated by the Pan article, which was published on December 12, 2006.  Id.

A copy of the Memorandum Opinion, which is comprehensive, is attached.  

[View source.]

Written by:

Fox Rothschild LLP
Contact
more
less

Fox Rothschild LLP on:

Reporters on Deadline

"My best business intelligence, in one easy email…"

Your first step to building a free, personalized, morning email brief covering pertinent authors and topics on JD Supra:
*By using the service, you signify your acceptance of JD Supra's Privacy Policy.
Custom Email Digest
- hide
- hide

This website uses cookies to improve user experience, track anonymous site usage, store authorization tokens and permit sharing on social media networks. By continuing to browse this website you accept the use of cookies. Click here to read more about how we use cookies.